09:53 AM EST - Trillium Therapeutics Inc. : Has dosed the first multiple myeloma patient with TTI-622 (SIRPa-IgG4 Fc), an investigational checkpoint inhibitor of the innate immune system, in combination with the proteasome inhibitor carfilzomib and dexamethasone. Trillium Therapeutics Inc.
shares T.TRIL are trading down $0.75 at $10.66.
